Hims & Hers Health stock tanks
Hims & Hers Health Stock Falls as FDA Drops Eli Lilly Weight-Loss Drugs From Shortage List
Key Takeaways Hims & Hers Health shares tumbled Thursday after the Food and Drug Administration (FDA) said Eli Lilly's popular weight-loss drugs are no longer on its list of drugs in short supply. The FDA allows companies to produce compounded copycat drugs when the originals are hard to obtain,
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
The FDA has resolved Eli Lilly's tirzepatide shortage, but localized supply issues persist. Meanwhile, Hims & Hers Health's Q3 2024 revenue is expected to exceed projections as concerns rise over compounded GLP-1 medications.
Hims & Hers Health stock tanks after FDA says competitor Eli Lilly’s weight-loss drug shortage is over
The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 medications. Shares of Hims & Hers Health fell almost 10% today following an announcement from the U.
Hims & Hers stock falls after Eli Lilly's weight-loss drug dropped from shortage list
Eli Lilly (LLY)'s weight loss drugs Mounjaro and Zepbound are no longer facing supply constraints, as the FDA has removed them from its shortage list — signaling the pharmaceutical giant's ability to now meet market demand.
The FDA issued a warning about compounding pharmacies on weight-loss drugs
A surge of alternatives to newly popular weight-loss drugs is facing its biggest test yet after the FDA warned companies against skirting regulatory standards to put them on the market now that shortages are waning.
What end of Eli Lilly's weight-loss drug shortage means for the competition
The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 diabetes drug Mounjaro, implying the company can now supply enough doses to meet current demand.
bovnews23h
The Hims & Hers Health Inc Enigma: What’s Causing the Wild Swings in HIMS Stock?
Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $17.66 which represents a slight increase of $0.53 or 3.09% from the prior close of $17.13. The stock opened at $17.55 and ...
Hims & Hers Health's Options Frenzy: What You Need to Know
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, ...
AOL27d
Hims & Hers Health Stock Is Crashing: Should You Buy the Dip?
Hims & Hers Health (NYSE: HIMS) has built its brand up in recent years by focusing on offering its customers products related to sensitive issues such as hair loss and erectile dysfunction.
Nasdaq28d
Is Hims & Hers Health Stock a Buy?
Telehealth company Hims & Hers Health (NYSE: HIMS) has been great for investors this year by almost any standard; share prices have nearly doubled from a year ago. Yet shareholders aren't feeling ...
Hims & Hers: The Gift That Keeps On Giving
Hims & Hers stock is currently in the middle of a deep drawdown. Read why I maintain my strong buy rating on HIMS stock.